160 related articles for article (PubMed ID: 38587730)
1. Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives.
Bergman AA; Oberman RS; Taylor SL; Kranke B; Chang ET
J Gen Intern Med; 2024 Apr; ():. PubMed ID: 38587730
[TBL] [Abstract][Full Text] [Related]
2. Clinical leaders and providers' perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs' facilities.
Hawkins EJ; Danner AN; Malte CA; Blanchard BE; Williams EC; Hagedorn HJ; Gordon AJ; Drexler K; Burden JL; Knoeppel J; Lott A; Sayre GG; Midboe AM; Saxon AJ
Addict Sci Clin Pract; 2021 Sep; 16(1):55. PubMed ID: 34488892
[TBL] [Abstract][Full Text] [Related]
3. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
4. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
Taylor EN; Timko C; Binswanger IA; Harris AHS; Stimmel M; Smelson D; Finlay AK
Subst Abus; 2022; 43(1):556-563. PubMed ID: 34586978
[No Abstract] [Full Text] [Related]
5. Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina.
Oros SM; Christon LM; Barth KS; Berini CR; Padgett BL; Diaz VA
Int J Psychiatry Med; 2021 Jan; 56(1):14-39. PubMed ID: 32726568
[TBL] [Abstract][Full Text] [Related]
6. Strategies to recruit rural primary care providers to implement a medication for opioid use disorder (MOUD) focused integrated care model.
Cloutier RM; Cole ES; McDonough BL; Lomauro DA; Miller JP; Talbert AL; Bear TM; Bridges NC; Foulds AL; Taber R; Gordon AJ; Cochran GT; Kmiec J; Donohue JM; Kelley D; DiDomenico E; Adair D; Pringle JL
Implement Res Pract; 2023; 4():26334895231152808. PubMed ID: 37091535
[TBL] [Abstract][Full Text] [Related]
7. Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers.
Pivovarova E; Taxman FS; Boland AK; Smelson DA; Lemon SC; Friedmann PD
J Subst Use Addict Treat; 2023 Apr; 147():208950. PubMed ID: 36804347
[TBL] [Abstract][Full Text] [Related]
8. Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder.
DeRonne BM; Wong KR; Schultz E; Jones E; Krebs EE
Am J Health Syst Pharm; 2021 Feb; 78(4):354-359. PubMed ID: 33326564
[TBL] [Abstract][Full Text] [Related]
9. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
[TBL] [Abstract][Full Text] [Related]
10. Barriers to Assessing and Treating Trauma in Primary Care and Opportunities for Improvement: Perspectives from Prescribers of Medications for Opioid Use Disorder.
Winiker AK; Heidari O; Pollock S; Sodder S; Tobin KE
Subst Use Misuse; 2023; 58(13):1651-1659. PubMed ID: 37495397
[No Abstract] [Full Text] [Related]
11. Increasing Access to Medications for Opioid Use Disorder and Complementary and Integrative Health Services in Primary Care.
Chang ET; Oberman RS; Cohen AN; Taylor SL; Gumm E; Mardian AS; Toy S; Revote A; Lewkowitz B; Yano EM
J Gen Intern Med; 2020 Dec; 35(Suppl 3):918-926. PubMed ID: 33145686
[TBL] [Abstract][Full Text] [Related]
12. Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics.
Ober AJ; Dopp AR; Clingan SE; Curtis ME; Lin C; Calhoun S; Larkins S; Black M; Hanano M; Osterhage KP; Baldwin LM; Saxon AJ; Hichborn EG; Marsch LA; Mooney LJ; Hser YI
J Subst Use Addict Treat; 2024 Jan; 156():209194. PubMed ID: 37863356
[TBL] [Abstract][Full Text] [Related]
13. Medications for opioid use disorder in rural primary care practices: Patient and provider experiences.
Bridges NC; Taber R; Foulds AL; Bear TM; Cloutier RM; McDonough BL; Gordon AJ; Cochran GT; Donohue JM; Adair D; DiDomenico E; Pringle JL; Gellad WF; Kelley D; Cole ES
J Subst Use Addict Treat; 2023 Nov; 154():209133. PubMed ID: 37543217
[TBL] [Abstract][Full Text] [Related]
14. Implementation of an office-based addiction treatment model for Medicaid enrollees: A mixed methods study.
Treitler P; Enich M; Bowden C; Mahone A; Lloyd J; Crystal S
J Subst Use Addict Treat; 2024 Jan; 156():209212. PubMed ID: 37935350
[TBL] [Abstract][Full Text] [Related]
15. Clinical stakeholders' perceptions of patient engagement in outpatient medication treatment for opioid use disorder: A qualitative study.
Poulsen MN; Roe SA; Asdell PB; Rahm AK; Berrettini W
J Subst Use Addict Treat; 2024 Mar; 158():209250. PubMed ID: 38072381
[TBL] [Abstract][Full Text] [Related]
16. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Scherer E; Marsch LA
J Subst Abuse Treat; 2020 Apr; 111():54-66. PubMed ID: 32076361
[TBL] [Abstract][Full Text] [Related]
17. "You have to take this medication, but then you get punished for taking it:" lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.
Schiff DM; Work EC; Muftu S; Partridge S; MacMillan KDL; Gray JR; Hoeppner BB; Kelly JF; Greenfield SF; Jones HE; Wilens TE; Terplan M; Bernstein J
J Subst Abuse Treat; 2022 Aug; 139():108765. PubMed ID: 35341614
[TBL] [Abstract][Full Text] [Related]
18. How a Medication for Opioid Use Disorder Curriculum Translates into Experiences and Internal Medicine Residents' Understanding of Patients with Opioid Use Disorder.
Robles M; Mortazavi L; Vannerson J; Matthias MS
Teach Learn Med; 2022; 34(5):514-521. PubMed ID: 33974460
[TBL] [Abstract][Full Text] [Related]
19. Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives.
Kelley AT; Wilcox J; Baylis JD; Crossnohere NL; Magel J; Jones AL; Gordon AJ; Bridges JFP
J Gen Intern Med; 2023 Jul; 38(9):2147-2155. PubMed ID: 36471194
[TBL] [Abstract][Full Text] [Related]
20. Application of the COM-B model to patient barriers and facilitators of retention in medication treatment for opioid use disorder in rural Northeastern United States: A qualitative study.
Poulsen MN; Asdell PB; Berrettini W; McBryan K; Rahm AK
SSM Ment Health; 2022 Dec; 2():. PubMed ID: 36776723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
